This invention relates to compounds of formula I
their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R
1
, R
2
, R
3
have meanings given in the description.
This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.
Studies in fluorinated β-diketones and related compounds—III
作者:Krishna C. Joshi、Vijai N. Pathak
DOI:10.1016/0022-1902(73)80015-6
日期:1973.9
Thirty-three new tetrakis rare earth chelate salts of the type: Piperidinium+ [(Ar-COCH-CO-R)4]−, have been prepared and characterized. Eighteen of these complexes have been examined for their fluorescence properties in solid state at 77°K. Correlations have been drawn between the fluorescence spectra and the possible site symmetries of the Eu3+ ion in europium tetrakis chelates. The i.r. of eighteen